Many drug companies are developing gene-based treatments for sickle cell and beta thalassemia, a related blood disorder. But Novartis and Precision say they still see a need for treatments that can work inside the body, rather than via stem cells edited in a laboratory, and can be deployed in countries where stem cell transplants can’t be easily carried out.
Read more here
 

The European Sickle Cell Federation officially launches its global campaign “Sickle Cell Has No Colour.. It’s in the Blood”, on World Sickle Cell Day june 19th 2022.
The campaign is to highlight the misconceptions relating to the racial structure of Sickle Cell Disease and its global prevalence.

Find more information on this campaign and the press release here.